Breaking News Instant updates and real-time market news.

ADT

ADT Inc.

$8.39

0.13 (1.57%)

, APHA

Aphria

$4.25

-0.175 (-3.96%)

08:45
11/18/19
11/18
08:45
11/18/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: ADT (ADT) 26.33% +1.41, Aphria (APHA) 52.20% +1.13, Revolve Group (RVLV) 20.69% +1.01, Turtle Beach (HEAR) 16.82% +0.80, Canopy Growth (CGC) 28.57% +0.58, Northern Dynasty (NAK) 20.85% +0.57, Financial Bear 3X (FAZ) 8.02% +0.22, CBL & Associates (CBL) 1.08% +0.20, CrowdStrike Holdings (CRWD) 17.34% +0.17, and Ballard Power (BLDP) 33.48% +0.16.

ADT

ADT Inc.

$8.39

0.13 (1.57%)

APHA

Aphria

$4.25

-0.175 (-3.96%)

RVLV

Revolve Group

$15.46

-0.17 (-1.09%)

HEAR

Turtle Beach

$8.68

-0.18 (-2.03%)

CGC

Canopy Growth

$15.33

-0.515 (-3.25%)

NAK

Northern Dynasty

$0.56

0.0053 (0.96%)

FAZ

Direxion Financial Bear 3x

$30.70

-0.25 (-0.81%)

CBL

CBL & Associates

$1.46

0.01 (0.69%)

CRWD

Crowdstrike

$59.79

6.96 (13.17%)

BLDP

Ballard Power

$6.91

0.33 (5.02%)

  • 19

    Nov

  • 05

    Dec

  • 12

    Dec

  • 19

    Dec

ADT ADT Inc.
$8.39

0.13 (1.57%)

05/13/19
MSCO
05/13/19
DOWNGRADE
Target $7
MSCO
Equal Weight
ADT Inc. downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Toni Kaplan downgraded ADT Inc. (ADT) to Equal Weight from Overweight as she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. The survey showed homeowners seem as inclined to buy DIY systems as ADT systems, that more ADT customers switched to DIY providers than she would have expected and that measure of brand preference for Amazon's (AMZN) Ring and Google's (GOOG) Nest were higher than for ADT, Kaplan explains. Given that the survey leads her to fear ADT may find it difficult to defend its market share, Kaplan lowered her price target on the stock to $7 from $9.
03/15/19
IMPC
03/15/19
NO CHANGE
Target $12
IMPC
Outperform
ADT Inc. price target lowered to $12 from $15 at Imperial Capital
Imperial Capital analyst Jeff Kessler lowered his price target for ADT Inc. to $12 from $15 saying "heavy" investment translated to reduced free cash flow guidance for 2019. The analyst, however, sees continued revenue growth for ADT and maintains an Outperform rating on the shares.
03/12/19
SBSH
03/12/19
DOWNGRADE
Target $8.25
SBSH
Neutral
ADT Inc. downgraded to Neutral from Buy at Citi
Cit downgraded ADT Inc. to Neutral from Buy and lowered its price target for the shares to $8.25 from $13. The firm sees a less certain free cash flow trajectory following ADT's Q4 results.
05/13/19
05/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Deere (DE) and Titan Machinery (TITN) downgraded to Neutral from Outperform at Baird. 2. Boot Barn (BOOT) downgraded to Hold from Buy at Pivotal Research with analyst Mitch Kummetz saying he sees a less favorable risk/reward at current share levels heading into the company's results on May 16. He does not see enough room for upside to his estimates, mainly because he believes oil and gas employment is becoming a "diminishing tailwind." 3. Shopify (SHOP) downgraded to Neutral from Buy at Guggenheim with analyst Ken Wong saying he sees upside potential as limited given the stock's current valuation, which he notes has now passed previous peak levels. 4. ADT Inc. (ADT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Toni Kaplan saying she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. 5. 51job (JOBS) downgraded to Neutral from Buy at Citi with analyst Alicia Yap saying she believes weakening operating metrics, such as a faster rate of decline for active employer count and slower rate of growth of ARPU, may be signals of challenges for online recruitment revenue growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
APHA Aphria
$4.25

-0.175 (-3.96%)

11/05/19
BOFA
11/05/19
NO CHANGE
BOFA
BofA says Mexico cannabis legalization 'still in play' in 2020 after extension
BofA Merrill Lynch analyst Christopher Carey noted that Mexico's Supreme Court has granted an extension until April 30, 2020 for Congress to legalize all forms of cannabis, writing in its decision that considering the complexity of the issue it grants the extension "exceptionally and for one time only." He views this as an important development for the industry since, in addition to opening a potentially large market, it will put even more pressure on U.S. federal action as the country will potentially "place the US between 2 of only 3 countries in the world to have legalized cannabis for recreational use." 9% of Mexico's population of 131M is estimated to have consumed cannabis in 2018 and the legal market could be worth $1B by 2024, according to BDS Analytics, noted Carey. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY) and Trulieve Cannabis (TCNNF).
10/16/19
BOFA
10/16/19
NO CHANGE
BOFA
BofA lowers cannabis stock price targets on further sales estimate changes
Following yesterday's rally in cannabis stock's driven by Aphria's (APHA) earnings, BofA Merrill Lynch analyst Christopher Carey said he doesn't see a case for sustainable upside yet until consensus estimates are cut further, which he thinks will ensue with the calendar Q3 results from the group. The reason that industry sales could be flat to down quarter-over-quarter sector-wide is that the cannabis industry is going from a period of inventory build to one of inventory "de-load," said Carey. Given his sales estimate revisions, he has lowered his price target on Aurora Cannabis (ACB) shares to $5 from $6, cut his Canopy Growth (CGC) price target to $23 from $27, trimmed his Cronos Group (CRON) target to $13 from $16 and decreased his Hexo (HEXO) target to $2 from $2.50. Carey keeps a Buy rating on Cronos, has Neutral ratings on Aurora and Canopy and maintains an Underperform rating on Hexo.
11/05/19
CANT
11/05/19
INITIATION
CANT
Overweight
Aphria initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Pablo Zuanic initiated coverage of Aphria with an Overweight rating and C$10.40 price target. The shares trade at a discount to peers even when adjusting for a large low-margin wholesale business in Germany, Zuanic tells investors in a research note. Further, he notes that Aphria management is confident that cannabis sales in the May fiscal year will be 10 times August quarter levels, due to ongoing market growth and share gains.
10/15/19
GHSC
10/15/19
NO CHANGE
Target $8
GHSC
Buy
Seaport Global says confidence in Buy rating on Aphria reinforced by earnings
Seaport Global analyst Brett Hundley said that in a Canadian cannabis market that "badly needed positive data points," Aphria reported "solid" Q1 results, including sequential growth top line growth in Canada and better then expected EBITDA of $1M. Cash burn was "within an acceptable range" and the company's over $500M pro-forma of available cash reinforces his confidence in his Buy rating, Hundley tells investors in a post-earnings research note. He maintains an $8 price target on Aphria shares.
RVLV Revolve Group
$15.46

-0.17 (-1.09%)

11/08/19
RAJA
11/08/19
NO CHANGE
Target $30
RAJA
Outperform
Revolve Group price target lowered to $30 from $40 at Raymond James
Raymond James analyst Aaron Kessler lowered his price target for Revolve Group to $30 from $40 saying the company's Owned brands growth slowed in Q3. This drove higher Owned brands inventory and lower full price sales, which also negatively impacted gross margins, Kessler tells investors in a research note. The analyst, however, believes Revolve Group's valuation remains attractive and he keeps an Outperform rating on the shares.
11/06/19
FBCO
11/06/19
NO CHANGE
Target $38
FBCO
Outperform
Revolve Group warrants valuation premium relative to peers, says Credit Suisse
Credit Suisse analyst Michael Binetti is keeping his Outperform rating and $38 price target on Revolve Group ahead of its Q3 results, saying the company's combination of established profitability and "strong" above 20% revenue growth is "increasingly scarce". The analyst notes that the upcoming quarter result may be less of an upside driver for the stock and warns that List 4 tariffs could limit 2019 guidance, but believes that the incremental risk has been priced in after a 26% decline in the stock price since the company's Q2 earnings call.
08/09/19
JEFF
08/09/19
NO CHANGE
Target $65
JEFF
Buy
Revolve Group price target raised to $65 from $60 at Jefferies
Jefferies analyst Randal Konik raised his price target for Revolve Group to $65 from $60 saying the company's Q2 results illustrate "robust" growth in active customers and orders, while its margins continue to rise. The quarter highlights the power of the Revolve platform to both aggregate consumers and influencers and scale profits, Konik tells investors in a research note. He keeps a Buy rating on the shares.
11/12/19
BARD
11/12/19
INITIATION
Target $26
BARD
Outperform
Revolve Group initiated with an Outperform at Baird
Baird initiated coverage of Revolve Group with an Outperform rating and $26 price target.
HEAR Turtle Beach
$8.68

-0.18 (-2.03%)

08/16/19
DADA
08/16/19
NO CHANGE
DADA
Buy
DA Davidson positive on Turtle Beach, Logitech after latest NPD gaming data
DA Davidson analyst Tom Forte keeps his Buy rating on Turtle Beach (HEAR) and Logitech (LOGI) with unchanged price targets of $26 and $58 respectively, saying investors should purchase the shares after the latest round of videogame industry data from NPD. The analyst notes that while accessory spending declined 12% in July, year-to-date spending is flat, which is "favorable" considering the tough comparison in the industry from last year's Fortnite craze. Forte further notes that Madden '20 was the best selling videogame in July and should be a catalyst for more headset sales given its "highly interactive" features.
05/09/19
DADA
05/09/19
NO CHANGE
Target $26
DADA
Buy
Turtle Beach price target raised to $26 from $23 at DA Davidson
DA Davidson analyst Tom Forte raised his price target on Turtle Beach to $26 and kept his Buy rating, saying the company's Q1 revenue and earnings beat were "extremely" encouraging. The analyst anticipated further sales upside for FY19 to come from more gaming publishers releasing "freemium" titles and a faster refresh cycle for Turtle Beach gaming accessory products.
11/08/19
LSCM
11/08/19
NO CHANGE
Target $17
LSCM
Buy
Turtle Beach price target lowered to $17 from $20 at Lake Street
Lake Street analyst Mark Argento lowered his price target for Turtle Beach to $17 from $20 citing the company's reduced guidance. The analyst, however, believes the current valuation is attractive and keeps a Buy rating on Turtle Beach shares.
11/08/19
DADA
11/08/19
NO CHANGE
Target $20
DADA
Buy
Turtle Beach price target lowered to $20 from $26 at DA Davidson
DA Davidson analyst Tom Forte lowered his price target on Turtle Beach to $20 after its in-line Q3 results and a cut in guidance. The analyst still keeps his Buy rating on the stock however and believes that 2020 comps will be much easier, with added potential catalyst of new gaming console launches in the back half of the year.
CGC Canopy Growth
$15.33

-0.515 (-3.25%)

11/15/19
BNCH
11/15/19
NO CHANGE
BNCH
Buy
Canopy Growth price target lowered to C$30 from C$60 at Benchmark
Benchmark analyst Mike Hickey lowered his price target on Canadian-traded shares of Canopy Growth to C$30 from C$60 following the company's "disappointing" Q2 performance, stating that he suspects investors are now favoring disciplined growth and a path to profitability given that the global and domestic cannabis market are not achieving the presumed near-term growth opportunity. He anticipates near-term performance trends will improve and keeps a Buy rating on Canopy shares, also citing future catalysts such as the opening of the U.S. CBD market and "Cannabis 2.0."
11/15/19
MKMP
11/15/19
NO CHANGE
MKMP
Canopy Growth, Aurora Cannabis price targets lowered at MKM Partners
MKM Partners analyst Bill Kirk lowered his price target on Neutral-rated Canopy Growth (CGC) to CAD23 from CAD30 and also lowered his price target on Sell-rated Aurora Cannabis (ACB) to CAD3.00 from CAD3.50 after their disappointing results. Canopy Growth saw an "astounding" EBITDA loss of CAD156M amid adjustment to revenue related to returns and pricing which, the analyst says, cannot be considered "one time". Kirk adds that the quarter echoes his concerns about the company's high inventory levels, noting that if Ontario doesn't open the stores that Canopy anticipates, those levels could again be too high. For Aurora Cannabis, the analyst states that the company's "cautious" plans to curtail capital spending by ceasing construction on Aurora Nordic 2 and the final construction of Aurora Sun suggests that investors should also be reluctant to deploy capital in the industry.
11/15/19
AGPP
11/15/19
DOWNGRADE
AGPP
Neutral
Canopy Growth downgraded to Neutral from Buy at Alliance Global Partners
Alliance Global Partners analyst Aaron Grey downgraded Canopy Growth to Neutral from Buy, stating that "the light [is] too far down the tunnel" to maintain a higher rating on the stock.
11/15/19
COMP
11/15/19
NO CHANGE
Target $17
COMP
Neutral
Canopy Growth price target lowered to $17 from $24 at Compass Point
Compass Point analyst Rommel Dionisio lowered his price target on Canopy Growth shares to $17 from $24 after the company reported "disappointing" Q2 results, including a sharp revenue shortfall that can be largely attributed to retailers lowering their inventory levels, a slower than expected pace of retail store openings, and continued overall pricing pressure in the Canadian market due to oversupply. While the advent of the sale of advanced forms of cannabis such as vapes and edibles in Canada in December should help, he remains concerned on overall Canadian pricing trends given the continued growth in production capacity and recent introduction of value-priced brands in flower/pre-rolls, said Dionisio, who keeps a Neutral rating on Canopy shares.
NAK Northern Dynasty
$0.56

0.0053 (0.96%)

FAZ Direxion Financial Bear 3x
$30.70

-0.25 (-0.81%)

CBL CBL & Associates
$1.46

0.01 (0.69%)

12/19/18
JPMS
12/19/18
DOWNGRADE
JPMS
Underweight
CBL & Associates downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Anthony Paolone downgraded CBL & Associates to Underweight. In addition to moving to a less constructive stance on the mall REITs as a group, the analyst believes that CBL's earnings growth will continue to be impacted in the near term by the carryover of headwinds from recent bankruptcies, rent reductions, and co-tenancy issues.
02/08/19
WELS
02/08/19
NO CHANGE
WELS
Wells downgrades Regional Mall REIT sector to Market Weight from Overweight
Wells Fargo analyst Jeffrey Donnelly reduced his rating on the Regional Mall REIT sector to Market Weight from Overweight. The ongoing "revenue disruption" from small-shop and anchor turnover combined with the anchor redevelopment initiatives will be a persistent source of earnings pressure in 2019 and 2020, Donnelly tells investors in a research note. Amid "low and decelerating" core earnings growth relative to other property types, the analyst believes "all but the very best capitalized companies may continue to trade as value ideas." He views Simon Property (SPG) as the dominant global player due to its "strong liquidity, robust balance sheet capacity, high-quality assets, and the depth of personnel capable of undertaking extensive redevelopment programs." Donnelly this morning also downgraded Macerich (MAC) to Market Perform from Outperform and kept an Underperform rating on CBL & Associates (CBL).
05/31/19
BTIG
05/31/19
UPGRADE
BTIG
Neutral
CBL & Associates upgraded to Neutral from Sell at BTIG
BTIG analyst James Sullivan upgraded CBL & Associates to Neutral from Sell.
05/31/19
05/31/19
UPGRADE

Neutral
CBL & Associates upgraded to Neutral from Sell at BTIG
In a regulatory filing, BTIG analyst James Sullivan upgraded CBL & Associates to Neutral, also lowering his 2019 EPS view by 3c to $1.40. The analyst cites his assumption of continued weaker same-store net operating income for the REIT along with a lower interest expense expected in 2020. Sullivan adds that some turnaround in operating performance could occur with the company's replacement program completed this year, but also notes that the operating metrics in the CBL portfolio "remain very weak."
CRWD Crowdstrike
$59.79

6.96 (13.17%)

10/23/19
NOMU
10/23/19
INITIATION
Target $65
NOMU
Buy
Nomura Instinet starts Crowdstrike with Buy rating, $65 price target
Nomura Instinet analyst Christopher Eberle initiated coverage of Crowdstrike with a Buy rating and $65 price target. The company is disrupting the endpoint security market with the introduction of its "modern, cloud-native security platform," Eberle tells investors in a research note. He believes "superior" proprietary technology, "rapid" customer adoption, and Crowdstrike's open architecture will continue to drive greater adoption both within security and beyond. As a result, the analyst expects the company's sales growth to continue to exceed expectations for "several years to come."
11/12/19
GSCO
11/12/19
UPGRADE
Target $55
GSCO
Neutral
Crowdstrike upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Heather Bellini upgraded Crowdstrike Holdings to Neutral from Sell with a price target of $55, down from $66. The shares closed Monday down $1.01 to $46.20. The analyst, who continues to view CrowdStrike as a leading next-generation endpoint security vendor, sees a more balanced risk/reward with the stock down 23% since her October 11 downgrade to Sell.
11/12/19
11/12/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Argo Group (ARGO) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Christopher Campbell saying he believes the company's "sizable" Q4 International reserve charge will restore balance sheet confidence and that new CEO Kevin Rehnberg's U.S. Operations outperformance can be replicated in its International segment. 2. Live Nation (LYV) upgraded to Outperform from In Line at Evercore ISI with analyst David Joyce saying he believes Live Nation shares have "pulled back needlessly" following its Q3 earnings results, and recommended taking advantage of the pullback. 3. Rent-A-Center (RCII) upgraded to Buy from Hold at Stifel with analyst John Baugh saying the recent pullback in the shares creates an attractive entry point. 4. Crowdstrike (CRWD) upgraded to Neutral from Sell at Goldman Sachs with analyst Heather Bellini she sees a more balanced risk/reward with the stock down 23% since her October 11 downgrade to Sell. 5. Teva (TEVA) upgraded to Neutral from Underweight at JPMorgan with analyst Christopher Schott citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/23/19
NOMU
10/23/19
INITIATION
Target $65
NOMU
Buy
Crowdstrike initiated with a Buy at Nomura Instinet
Nomura Instinet started Crowdstrike with a Buy rating and $65 price target.
BLDP Ballard Power
$6.91

0.33 (5.02%)

11/01/19
HCWC
11/01/19
DOWNGRADE
HCWC
Neutral
Ballard Power downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Amit Dayal downgraded Ballard Power Systems to Neutral from Buy without a price target. The analyst says Ballard's stock has exceeded his previous price target of $4.50 while the outlook provided on its Q3 earnings call does not materially revise his expectations for the company. Dayal, however, remains bullish on the adoption of fuel cells and the emergence of hydrogen as a growing part of the global energy mix. He also continues to expect Ballard to maintain its leadership in this market. However, at current levels near-term expectations are adequately reflected in the stock price, he contends.
07/01/19
07/01/19
DOWNGRADE
Target $3

Sell
Ballard Power downgraded to Sell on valuation at Roth Capital
As previously reported, Roth Capital analyst Craig Irwin downgraded Ballard Power to Sell from Neutral, while maintained a $3 price target on the shares, as he believes positive China fuel cell market exposure does not justify the valuation. Current valuation is near 15-year highs, and is unlikely to see internet-type multiples last seen in 2001, he contends. While the analyst agrees the company's supply relationships with groups like Weichai and BroadOcean position it well to benefit from China market tailwinds, Ballad does not offer a hydrogen electrolyzer solutions necessary for refueling infrastructure.
07/01/19
ROTH
07/01/19
DOWNGRADE
ROTH
Sell
Ballard Power downgraded to Sell from Neutral at Roth Capital
Roth Capital analyst Craig Irwin downgraded Ballard Power to Sell from Neutral and maintained a $3 price target citing recent share strength and a valuation near 15-year highs.
11/01/19
LSCM
11/01/19
NO CHANGE
Target $6
LSCM
Buy
Ballard Power price target raised to $6 from $5 at Lake Street
Lake Street analyst Robert Brown raised his price target for Ballard Power Systems to $6 from $5 saying the company is executing well following its inline Q3 results. Trends appear to be strengthening globally with activity in the European bus and China truck markets as well as a new development program for a mine truck, Brown tells investors in a post-earnings research note. He keeps a Buy rating on Ballard Power.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
12/06/19
12/06
13:17
12/06/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
12/06/19
12/06
13:16
12/06/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,749.41

8.82 (0.51%)

13:08
12/06/19
12/06
13:08
12/06/19
13:08
Periodicals
Amazon says U.K. soccer streams brought record Prime sign-ups, Guardian says »

Amazon has said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKR

Baker Hughes

$22.28

0.14 (0.63%)

13:05
12/06/19
12/06
13:05
12/06/19
13:05
Hot Stocks
Baker Hughes reports U.S. rig count down 3 to 799 rigs »

Baker Hughes reports the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$89.77

-0.14 (-0.16%)

, PSN

Parsons

$40.51

0.66 (1.66%)

13:00
12/06/19
12/06
13:00
12/06/19
13:00
Recommendations
Leidos, Parsons analyst commentary  »

Wells says investors…

LDOS

Leidos

$89.77

-0.14 (-0.16%)

PSN

Parsons

$40.51

0.66 (1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

SPY

SPDR S&P 500 ETF Trust

$315.21

3.17 (1.02%)

, VOO

Vanguard S&P 500 ETF

$289.57

2.94 (1.03%)

12:58
12/06/19
12/06
12:58
12/06/19
12:58
Technical Analysis
On The Fly: ETF fund flow highlights »

For the week flows to the…

SPY

SPDR S&P 500 ETF Trust

$315.21

3.17 (1.02%)

VOO

Vanguard S&P 500 ETF

$289.57

2.94 (1.03%)

XLY

Consumer Discretionary Sector SPDR

$121.97

1.19 (0.99%)

XLI

Industrial Select Sector SPDR

$81.21

1.08 (1.35%)

IEF

iShares 7-10 Year Treasury Bond ETF

$110.99

-0.34 (-0.31%)

GLD

SPDR Gold Shares

$137.61

-1.4 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$234.00

0.56 (0.24%)

, JNJ

Johnson & Johnson

$141.00

1.43 (1.02%)

12:53
12/06/19
12/06
12:53
12/06/19
12:53
Hot Stocks
FDA approves Amgen's Avsola »

The U.S. Food and Drug…

AMGN

Amgen

$234.00

0.56 (0.24%)

JNJ

Johnson & Johnson

$141.00

1.43 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

SYPR

Sypris Solutions

$0.82

(0.00%)

, UTX

United Technologies

$147.18

1.87 (1.29%)

12:52
12/06/19
12/06
12:52
12/06/19
12:52
Hot Stocks
Sypris subsidiary wins contracts with United Technologies' Collins Aerospace »

Sypris Electronics, a…

SYPR

Sypris Solutions

$0.82

(0.00%)

UTX

United Technologies

$147.18

1.87 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

LDOS

Leidos

$89.47

-0.44 (-0.49%)

12:49
12/06/19
12/06
12:49
12/06/19
12:49
Hot Stocks
Leidos among team awarded DOE contract for Hanford site services »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMU

Immunomedics

$20.38

1.86 (10.04%)

12:45
12/06/19
12/06
12:45
12/06/19
12:45
Options
Immunomedics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

12:45
12/06/19
12/06
12:45
12/06/19
12:45
General news
Breaking General news story  »

Week of 12/6 Baker-Hughes…

12:45
12/06/19
12/06
12:45
12/06/19
12:45
General news
Breaking General news story  »

Week of 12/6 Baker-Hughes…

12:40
12/06/19
12/06
12:40
12/06/19
12:40
General news
Treasury's $25 B 2-year FRN reopening stopped at 0.245% »

Treasury's $25 B…

12:40
12/06/19
12/06
12:40
12/06/19
12:40
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

12:30
12/06/19
12/06
12:30
12/06/19
12:30
General news
Treasury's $25 B 2-year FRN reopening stopped at 0.245% »

Treasury's $25 B…

PIR

Pier 1 Imports

$7.70

-0.27 (-3.39%)

12:22
12/06/19
12/06
12:22
12/06/19
12:22
Periodicals
Pier 1 hired Guggenheim amid concerns over debt, Debtwire reports »

Pier 1 Imports has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLA

Medallia

$29.11

-0.68 (-2.28%)

12:19
12/06/19
12/06
12:19
12/06/19
12:19
Recommendations
Medallia analyst commentary  »

Oppenheimer says would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

PIR

Pier 1 Imports

$7.92

-0.05 (-0.63%)

12:19
12/06/19
12/06
12:19
12/06/19
12:19
Periodicals
Breaking Periodicals news story on Pier 1 Imports »

Pier 1 hired financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
12/06/19
12/06
12:17
12/06/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
12/06/19
12/06
12:16
12/06/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$60.70

1.195 (2.01%)

, XLRN

Acceleron

$48.58

-0.08 (-0.16%)

12:08
12/06/19
12/06
12:08
12/06/19
12:08
Hot Stocks
Bristol-Myers, Acceleron: FDA says Reblozyl will not be reviewed at ODAC meeting »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$60.70

1.195 (2.01%)

XLRN

Acceleron

$48.58

-0.08 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

  • 04

    Apr

MNTA

Momenta

$17.53

0.68 (4.04%)

12:04
12/06/19
12/06
12:04
12/06/19
12:04
Hot Stocks
Momenta granted orphan status for hemolytic anemia treatment »

The FDA granted Momenta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 16

    Dec

EA

Electronic Arts

$102.74

0.66 (0.65%)

, ATVI

Activision Blizzard

$55.08

0.09 (0.16%)

12:03
12/06/19
12/06
12:03
12/06/19
12:03
Conference/Events
Wedbush digital media analyst to hold an analyst/industry conference call »

Digital Media Analyst…

EA

Electronic Arts

$102.74

0.66 (0.65%)

ATVI

Activision Blizzard

$55.08

0.09 (0.16%)

GME

GameStop

$6.46

0.1 (1.57%)

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$123.21

-0.69 (-0.56%)

UBSFY

Ubisoft

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 13

    Dec

PRVL

Prevail Therapeutics

$14.02

-0.03 (-0.21%)

12:02
12/06/19
12/06
12:02
12/06/19
12:02
Hot Stocks
Prevail Therapeutics granted orphan status for dementia treatment »

The FDA granted Prevail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEI

Weidai

$4.10

-0.35 (-7.87%)

12:00
12/06/19
12/06
12:00
12/06/19
12:00
Hot Stocks
Weidai falls -8.3% »

Weidai is down -8.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.